Vigeo Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that effectively treat various types of cancer, ultimately improving patients' lives. With a focus on reprogramming the tumor immune microenvironment (TIME), Vigeo is building a first-in-class drug discovery pipeline. By targeting thrombospondin-1 (Tsp-1), a naturally occurring anti-tumorigenic protein and one of the body's own defenses against cancer, Vigeo therapies aim to activate CD36 and CD47 pathways to attack cancer cells and prevent their spread.

Currently, Vigeo is conducting clinical trials on VT1021, a peptide therapeutic agent, enrolling patients with pancreatic, ovarian, triple-negative breast cancers, glioblastoma, and tumors with high amounts of CD36. These trials aim to provide valuable insights and advance treatment outcomes for these challenging diseases. If you're looking to join the fight against cancer, Vigeo offers exciting career opportunities.

Stay updated on the latest news and breakthroughs in cancer therapy by visiting Vigeo's website. Together, let's beat cancer